A decade of immune-checkpoint inhibitors in cancer therapy

By C. Robert. Nature Communications, 2020

1,352 citations recorded by the source corpus.

Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/27490e6c7fb98521bc99306914ec3b9ad9dff740

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Y. Shiravand
2. R. Ladwa
3. K. O'Byrne
4. S. R. Hosseini-Fard
5. Faezeh Khodadadi
6. Seyyed Mohammad Amin Kashani
7. H. Sadeghirad
8. Shadi Hosseini

Citations in the corpus

• Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes (Table 1) [13].”